title: Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast.
abstract: OBJECTIVE
  The distal airways are likely to contribute to asthma pathobiology and symptoms but have rarely been specifically evaluated in relation to systemic oral therapy. We hypothesized that treatment with montelukast, an oral cysteinyl-leukotriene receptor antagonist, would improve both proximal and distal lung physiology in patients with mild asthma.
  
  
  METHODS
  Randomized, double-blind, crossover design.
  
  
  METHODS
  Academic referral center.
  
  
  METHODS
  Subjects with mild asthma limited to using short-acting inhaled beta(2)-agonists.
  
  
  METHODS
  Nineteen subjects with mild asthma underwent a baseline assessment of lung function, lung mechanics, and symptoms, followed by randomization to therapy with montelukast, 10 mg taken in the evening, or placebo in a crossover, double-blind fashion. Each treatment phase lasted 4 weeks, with a 2-week washout period. A repeat evaluation was performed during the last week of each treatment phase.
  
  
  RESULTS
  Montelukast resulted in improvement in (mean +/- SD) proximal and distal lung function parameters (change in FEV(1): montelukast, 0.16 +/- 0.06 L; placebo, -0.05 +/- 0.05 L; p = 0.008); change in specific conductance: montelukast, 7.2 +/- 2.9% predicted; placebo, -17 +/- 8% predicted; p = 0.007; change in % predicted residual volume [RV]: montelukast, 18.4 +/- 8.3% predicted; placebo, 3.0 +/- 2.9% predicted; p = 0.05). Improvement in symptoms (ie, wheeze and chest tightness) correlated with improvements in RV while receiving montelukast, but not while receiving placebo (Pearson coefficients: 0.55 and 0.66, respectively; p < 0.008 and 0.04, respectively).
  
  
  CONCLUSIONS
  The systemically acting oral agent montelukast improves proximal and distal lung physiology. Improvements in distal lung function correlate with improvements in asthma symptoms.
authors.affiliation: Department of Medicine, Duke University Medical Center, MSBR M201D, Durham, NC 27710, USA. Monica.Kraft@duke.edu
authors.forename: Monica
authors.initials: M
authors.lastname: Kraft
authors.forename: Charles B
authors.initials: CB
authors.lastname: Cairns
authors.forename: Misoo C
authors.initials: MC
authors.lastname: Ellison
authors.forename: Juno
authors.initials: J
authors.lastname: Pak
authors.forename: Charles
authors.initials: C
authors.lastname: Irvin
authors.forename: Sally
authors.initials: S
authors.lastname: Wenzel
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D018592:Cross-Over Studies; D003521:Cyclopropanes; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects*; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000627:therapeutic use*; D012115:Residual Volume / Q000187:drug effects*; D015656:Respiratory Mechanics / Q000187:drug effects*; D013223:Statistics as Topic; D013440:Sulfides; D014797:Vital Capacity / Q000187:drug effects*
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast